These 2 Biotech Stocks Are Set to Soar
Investing in biotech companies, especially relatively small ones, can be a double-edged sword. Their shares often soar on strong clinical trial or regulatory news, but they can lose much of their value overnight if a study's results don't go their way. That makes many biotech stocks somewhat risky investments, but some could deliver excellent results for those who can stomach the risk.
Two biotech companies whose shares could gain significant traction in the months and years ahead are Viking Therapeutics (NASDAQ: VKTX) and Sarepta Therapeutics (NASDAQ: SRPT).
Viking Therapeutics is a clinical-stage biotech whose stock rose significantly this year. The drugmaker owes that run-up to its leading candidate, VK2735, a potential GLP-1 weight loss therapy that produced strong results in a phase 2 study. At least two scenarios could lead to Viking's shares soaring even more in the coming months and years.
Source Fool.com
Viking Therapeutics Inc Stock
With 6 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 110 € shows a very positive potential of 82.6% compared to the current price of 60.24 € for Viking Therapeutics Inc.
